Abstract:Sphingomyelin plays a very important role both in cell membrane formation that may well have an impact on the development of diseases like atherosclerosis and diabetes. However, the molecular mechanism that governs intracellular and plasma membrane SM levels is largely unknown. Recently, two isoforms of sphingomyelin synthase (SMS1 and SMS2), the last enzyme for SM de novo synthesis, have been cloned. We have hypothesized that SMS1 and SMS2 are the two most likely candidates responsible for the SM levels in the cells and on the plasma membrane. To test this hypothesis, cultured cells were treated with tricyclodecan-9-yl-xanthogenate (D609), an inhibitor of SMS, or with SMS1 and SMS2 siRNAs. Cells were then pulsed with [14C]-L-serine (a precursor of all sphingolipids). SMS activity and [14C]-SM in the cells were monitored. We found that SMS activity was significantly decreased in cells after D609 or SMS siRNA treatment, compared with controls. SMS inhibition by D609 or SMS siRNAs significantly decreased intracellular [14C]-SM levels. We measured cellular lipid levels, including SM, ceramide, phosphatidylcholine, and diacylglycerol and found that SMS1 and SMS2 siRNA treatment caused a significant decrease of SM levels (20% and 11%, respectively), compared to control siRNA treatment; SMS1 but not SMS2 siRNA treatment caused a significant increase of ceramide levels (10%). There was a decreasing tendency for diacylglycerol levels after both SMS1 and SMS2 siRNA treatment, however, it was not statistical significant. As shown by lipid rafts isolation and lipid determination, SMS1 and SMS2 siRNA treatment led to a decrease of SM content in detergent-resistant lipid rafts on the cell membrane. Furthermore, SMS1 and SMS2 siRNA-treated cells had a stronger resistance than did control siRNA-treated cells to lysenin (a protein that causes cell lysis due to its affinity for plasma membrane SM). These results indicate that both SMS1 and SMS2 contribute to SM de novo synthesis and control SM levels in the cells and on the cell membrane including plasma membrane, implying an important relationship between SMS activity and cell functions.

Molecular Modeling of the Three-Dimensional Structure of Human Sphingomyelin Synthase

Molecular Basis for the Catalytic Mechanism of Human Neutral Sphingomyelinases 1 (Hsmpd2).

Cryo-EM Structure of Human Sphingomyelin Synthase and Its Mechanistic Implications for Sphingomyelin Synthesis

Identification of Small Molecule Sphingomyelin Synthase Inhibitors.

Structure-based Rational Quest for Potential Novel Inhibitors of Human HMG-CoA Reductase by Combining CoMFA 3D QSAR Modeling and Virtual Screening.

The domain responsible for sphingomyelin synthase (SMS) activity.

Discovery, Synthesis and Biological Evaluation of 2-(4-(n-phenethylsulfamoyl)phenoxy)acetamides (sapas) As Novel Sphingomyelin Synthase 1 Inhibitors

Development of a Quantitative Biochemical and Cellular Sphingomyelin Synthase Assay Using Mass Spectrometry

Discovery of the Selective Sphingomyelin Synthase 2 Inhibitors with the Novel Structure of Oxazolopyridine

Discovery of 4-Benzyloxybenzo[d]isoxazole-3-amine Derivatives As Highly Selective and Orally Efficacious Human Sphingomyelin Synthase 2 Inhibitors That Reduce Chronic Inflammation in Db/db Mice

SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglycerol metabolism, and cell apoptosis

Inhibition of Sphingomyelin Synthase (SMS) Affects Intracellular Sphingomyelin Accumulation and Plasma Membrane Lipid Organization.

Machine learning models to identify lead compound and substitution optimization to have derived energetics and conformational stability through docking and MD simulations for sphingosine kinase 1

Subcellular Targeting Domains of Sphingomyelin Synthase 1 and 2

A facile method for monitoring sphingomyelin synthase activity in HeLa cells using liquid chromatography/mass spectrometry

Analysis of Fluorescent Ceramide and Sphingomyelin Analogs: A Novel Approach for in Vivo Monitoring of Sphingomyelin Synthase Activity

QSAR Modeling of Sphingomyelin Synthase 2 Inhibitors for Their Potential as Anti-Atherosclerotic Agents

Effect of Mutations on Drug Resistance of Smoothened Receptor Toward Inhibitors Probed by Molecular Modeling

Design and Synthesis of the Diazirine-based Clickable Photo-affinity Probe Targeting Sphingomyelin Synthase 2

Computational model of sphingolipids metabolism: a case study of Alzheimer's disease

Rational design of SphK inhibitors using crystal structures aided by computer